Top

Published in:

01-06-2021 | Systemic Lupus Erythematosus | Case Based Review

A case of eosinophilic fasciitis without skin manifestations: a case report in a patient with lupus and literature review

Authors: Kohei Asaoka, Yuki Watanabe, Kazuhiro Itoh, Naoko Hosono, Tomoya Hirota, Masamichi Ikawa, Tomohisa Yamaguchi, Satomi Hatta, Yoshiaki Imamura, Ichizo Nishino, Takahiro Yamauchi, Hiromichi Iwasaki

Published in: Clinical Rheumatology | Issue 6/2021

Abstract

Eosinophilic fasciitis (EF) is a rare connective tissue disease that causes inflammation and fibrosis of the fascia, inducing pain and motor dysfunction. Characteristic skin manifestations, such as edema, erythema, induration, peau d’orange appearance, and the groove sign, are of diagnostic significance and observed in the majority of patients with EF. We herein report a case of EF without these characteristic skin manifestations. A 66-year-old Japanese woman developed progressive limb pain and motor dysfunction. No skin changes were observed. We diagnosed the patient with EF based on the clinical course, magnetic resonance imaging, and en bloc biopsy containing fascia and muscle. Oral prednisolone therapy markedly attenuated limb pain and motor dysfunctions. Through a systemic search of the medical literature, we retrieved 4 juvenile cases and 8 adult cases of EF without characteristic skin manifestations during the clinical course. We herein present a systemic review on EF without skin manifestations and discuss differences between the two proposed sets of diagnostic criteria of EF.

Shulman LE (1984) Diffuse fasciitis with hypergammaglobulinemia and eosinophilia: a new syndrome? J Rheumatol 11(5):569–570PubMed

Fett N, Arthur M (2018) Eosinophilic fasciitis: current concepts. Clin Dermatol 36(4):487–497. https://doi.org/10.1016/j.clindermatol.2018.04.006CrossRefPubMed

Mango RL, Bugdayli K, Crowson CS, Drage LA, Wetter DA, Lehman JS, Peters MS, Davis MD, Chowdhary VR (2020) Baseline characteristics and long-term outcomes of eosinophilic fasciitis in 89 patients seen at a single center over 20 years. Int J Rheum Dis 23(2):233–239. https://doi.org/10.1111/1756-185X.13770CrossRefPubMed

Lakhanpal S, Ginsburg WW, Michet CJ, Doyle JA, Moore SB (1988) Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum 17(4):221–231. https://doi.org/10.1016/0049-0172(88)90008-xCrossRefPubMed

Wright NA, Mazori DR, Patel M, Merola JF, Femia AN, Vleugels RA (2016) Epidemiology and treatment of eosinophilic fasciitis: an analysis of 63 patients from 3 tertiary care centers. JAMA Dermatol 152(1):97–99. https://doi.org/10.1001/jamadermatol.2015.3648CrossRefPubMed

Mazori DR, Femia AN, Vleugels RA (2017) Eosinophilic fasciitis: an updated review on diagnosis and treatment. Curr Rheumatol Rep 19(12):74. https://doi.org/10.1007/s11926-017-0700-6CrossRefPubMed

Kurimoto R, Ikeda K, Nakagomi D, Nakajima H (2016) Eosinophilic fasciitis illustrated by [(18)F] FDG-PET/CT. Intern Med (Tokyo, Japan) 55(16):2321–2322. https://doi.org/10.2169/internalmedicine.55.6937CrossRef

Suzuki S, Noda K, Ohira Y, Shikino K, Ikusaka M (2015) Finger stiffness or edema as presenting symptoms of eosinophilic fasciitis. Rheumatol Int 35(10):1769–1772. https://doi.org/10.1007/s00296-015-3338-6CrossRefPubMed

Thönnes S, Sorg H, Hauser J, Tilkorn DJ (2017) Localized eosinophilic fasciitis (Shulman’s disease) as a differential diagnosis of nerve compression syndrome. Innov Surg Sci 2(1):23–25. https://doi.org/10.1515/iss-2016-0203CrossRefPubMedPubMedCentral

10.

Pillen S, van Engelen B, van den Hoogen F, Fiselier T, van der Vossen P, Drost G (2006) Eosinophilic fasciitis in a child mimicking a myopathy. Neuromuscul Disord 16(2):144–148. https://doi.org/10.1016/j.nmd.2005.12.001CrossRefPubMed

11.

Huppke P, Wilken B, Brockmann K, Sattler B, Hanefeld F (2002) Eosinophilic fasciitis leading to painless contractures. Eur J Pediatr 161(10):528–530. https://doi.org/10.1007/s00431-002-1038-1CrossRefPubMed

12.

Papa R, Nozza P, Granata C, Caorsi R, Gattorno M, Martini A, Picco P (2016) Juvenile eosinophilic fasciitis: three case reports with review of the literature. Clin Exp Rheumatol 34(3):527–530PubMed

13.

Lebeaux D, Francès C, Barete S, Wechsler B, Dubourg O, Renoux J, Maisonobe T, Benveniste O, Gatfossé M, Bourgeois P, Amoura Z, Cacoub P, Piette JC, Sène D (2012) Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients. Rheumatology (Oxford, England) 51(3):557–561. https://doi.org/10.1093/rheumatology/ker366CrossRef

14.

Tsoi KL, Custers M, Bij de Vaate L, Jacobs JW (2012) Eosinophilic fasciitis. BMJ Case Rep. https://doi.org/10.1136/bcr.2012.6158

15.

Suresh E, Doherty V, Schofield O, Goddard C, Dhillon V (2005) Eosinophilic fasciitis and eosinophilic colitis: a rare association. Rheumatology (Oxford, England) 44(3):411–413. https://doi.org/10.1093/rheumatology/keh510CrossRef

16.

Huemer M, Seeber A, Huemer C (2000) Scleroderma-like syndrome in a child: eosinophilic fasciitis or scleredema adultorum? Eur J Pediatr 159(7):520–522. https://doi.org/10.1007/s004310051323CrossRefPubMed

17.

Ching DW, Petrie JP (1991) Childhood eosinophilic fasciitis presenting as inflammatory polyarthritis and associated with selective IgA deficiency. Ann Rheum Dis 50(9):647–648. https://doi.org/10.1136/ard.50.9.647CrossRefPubMedPubMedCentral

18.

Barnes L, Rodnan GP, Medsger TA, Short D (1979) Eosinophilic fasciitis. A pathologic study of twenty cases. Am J Pathol 96(2):493–518PubMedPubMedCentral

19.

Uruha A, Nishikawa A, Tsuburaya RS, Hamanaka K, Kuwana M, Watanabe Y, Suzuki S, Suzuki N, Nishino I (2017) Sarcoplasmic MxA expression: a valuable marker of dermatomyositis. Neurology 88(5):493–500. https://doi.org/10.1212/WNL.0000000000003568CrossRefPubMed

20.

Tanboon J, Nishino I (2019) Classification of idiopathic inflammatory myopathies: pathology perspectives. Curr Opin Neurol 32(5):704–714. https://doi.org/10.1097/WCO.0000000000000740CrossRefPubMed

21.

Suzuki S, Yonekawa T, Kuwana M, Hayashi YK, Okazaki Y, Kawaguchi Y, Suzuki N, Nishino I (2014) Clinical and histological findings associated with autoantibodies detected by RNA immunoprecipitation in inflammatory myopathies. J Neuroimmunol 274(1-2):202–208. https://doi.org/10.1016/j.jneuroim.2014.07.006CrossRefPubMed

22.

Noguchi E, Uruha A, Suzuki S, Hamanaka K, Ohnuki Y, Tsugawa J, Watanabe Y, Nakahara J, Shiina T, Suzuki N, Nishino I (2017) Skeletal muscle involvement in antisynthetase syndrome. JAMA Neurol 74(8):992–999. https://doi.org/10.1001/jamaneurol.2017.0934CrossRefPubMedPubMedCentral

23.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Johnson SR (2019) 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol (Hoboken, N.J.) 71(9):1400–1412. https://doi.org/10.1002/art.40930CrossRef

24.

García-Morteo O, Nitsche A, Maldonado-Cocco JA, Barceló HA (1987) Eosinophilic fasciitis and retroperitoneal fibrosis in a patient with systemic lupus erythematosus. Arthritis Rheum 30(11):1314–1315. https://doi.org/10.1002/art.1780301118CrossRefPubMed

25.

Sills EM (1988) Systemic lupus erythematosus in a patient previously diagnosed as having Shulman disease. Arthritis Rheum 31(5):694–695. https://doi.org/10.1002/art.1780310519CrossRefPubMed

26.

Baffoni L, Frisoni M, Maccaferri M, Ferri S (1995) Systemic lupus erythematosus and eosinophilic fasciitis: an unusual association. Clin Rheumatol 14(5):591–592. https://doi.org/10.1007/BF02208164CrossRefPubMed

27.

Gallardo F, Vadillo M, Mitjavila F, Servitje O (1998) Systemic lupus erythematosus after eosinophilic fasciitis: a case report. J Am Acad Dermatol 39(2 Pt 1):283–285. https://doi.org/10.1016/s0190-9622(98)70091-xCrossRefPubMed

28.

Kitamura Y, Hatamochi A, Hamasaki Y, Ikeda H, Yamazaki S (2007) Association between eosinophilic fasciitis and systemic lupus erythematosus. J Dermatol 34(2):150–152. https://doi.org/10.1111/j.1346-8138.2006.00238.xCrossRefPubMed

29.

Mrabet D, Saadi F, Chelly I, Trojet S, Zaraa I, Sahli H, Haouet S, Ben Osmane A, Meddeb N, Sellami S (2010) A case of Shulman disease in a patient with systemic lupus erythematosus. Lupus 19(14):1674–1675. https://doi.org/10.1177/0961203310376524CrossRefPubMed

30.

Pinal-Fernandez I, Selva-O'Callaghan A, Grau JM (2014) Diagnosis and classification of eosinophilic fasciitis. Autoimmun Rev 13(4-5):379–382. https://doi.org/10.1016/j.autrev.2014.01.019CrossRefPubMed

31.

Ihn H (2019) Eosinophilic fasciitis: from pathophysiology to treatment. Allergol Int: Off J JapanSoc Allergol 68(4):437–439. https://doi.org/10.1016/j.alit.2019.03.001CrossRef

Title: A case of eosinophilic fasciitis without skin manifestations: a case report in a patient with lupus and literature review
Authors: Kohei Asaoka
Yuki Watanabe
Kazuhiro Itoh
Naoko Hosono
Tomoya Hirota
Masamichi Ikawa
Tomohisa Yamaguchi
Satomi Hatta
Yoshiaki Imamura
Ichizo Nishino
Takahiro Yamauchi
Hiromichi Iwasaki
Publication date: 01-06-2021
Publisher: Springer International Publishing
Keywords: Systemic Lupus Erythematosus
Eosinophilic Fasciitis
Prednisolone
Published in: Clinical Rheumatology / Issue 6/2021
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-05416-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2021

Acute severe hepatitis in adult-onset Still’s disease: case report and comprehensive review of a life-threatening manifestation

Outcomes and predictors of juvenile idiopathic arthritis in Southeast Asia: a Singapore longitudinal study over a decade

The relationship between restless sleep and symptoms of the knee: data from the Osteoarthritis Initiative

Correction to: Investigation of the relationships between knee osteoarthritis and obesity via untargeted metabolomics analysis

Lower education is an associated factor with the combination of pain catastrophizing and kinesiophobia in patients with knee osteoarthritis?

Impact of COVID-19 on rheumatology practice in the UK—a pan-regional rheumatology survey

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials